Skip to main content
. 2020 Mar 17;15(3):e0229184. doi: 10.1371/journal.pone.0229184

Fig 2. Relationship between sLOX-1 and SLE-related complement levels, platelets, WBC, erythrocyte sedimentation rate (ESR), SLEDAI scores and cytokines.

Fig 2

Stratification of lupus clinical and serological parameters based on low and high sLOX-1 levels. Measurement of Complement (A) C3 mg/dL (93.12 ± 1.873, n = 171 versus 111.1 ± 2.95, n = 102) and (B) C4 mg/dL (18.48 ± 0.69, n = 171 versus 21.53 ± 0.9336, n = 102), (C) platelets (228.1 ± 5.718 (#/uL whole blood), n = 171 versus 249.7 ± 6.524, n = 103), (D) WBC (5.157 ± 0.1567 (K/uL), n = 170 versus 6.51 ± 0.2547, n = 102), (E) ESR mm/hr (27.21 ± 1.689, n = 169 versus 26.33 ± 2.127, n = 101) low sLOX-1 versus high sLOX-1 mean and SEM. (F) sLOX-1 levels binned by SLEDAI score. Bars represent mean±SEM sLOX-1 values for no (745±67.95 n = 104), mild 495±46 n = 127), moderate (383.4±65.41 n = 29) and severe (558.1±210.9 n = 11) disease activity. (G) Cytokines IFN-γ, IL-8, IL-10, IL-6 and TNF-α were measured by multiplex MSD ELISAs from SLE patients in the low sLOX-1 (n = 141) and high sLOX-1 (n = 101) groups. * p<0.05, ** p<0.01, ***p<0.001 and ****p<0.0001.